OUR PRODUCTS ALREADY AVAILABLE FOR PHARMA, BIOTECH & CROs
Predict Anti-Cancer Drug Efficacy with Confidence
Validated across 7 real-world studies and 250+ patient samples, CaliPower delivers exceptional predictive accuracy by integrating multi-omics assays on patients’ tumor specimens with advanced algorithmic modeling. Its scoring system demonstrates a robust correlation with Objective Response Rate (ORR), providing a powerful surrogate for clinical outcomes.
This capability enables early efficacy prediction, biomarker-driven patient selection, and adaptive trial design, helping you prioritize high-value candidates, optimize dosing strategies, and accelerate preclinical-to-clinical bridging. By leveraging patients’ tumor data, CaliPower supports regulatory submissions with mechanistic evidence and predictive analytics, reducing development risk and resource waste.
With CaliPower, you make faster, smarter decisions in oncology drug development, ensuring your pipeline is guided by clinically relevant insights from the start.
Correlation between CaliPower Score and ORR. Each dot represents a CaliPower project, with at least 30 samples each, treated with a single or combination of anti-cancer drugs. ORR from cohorts of matching patient with available clinical data were used
Understand Why Your Drug Works—and How to Make It Better
CaliHow delivers comprehensive mechanistic insights into your therapeutic candidate, revealing its mechanism of action (MoA) and translational relevance within the tumor microenvironment. This knowledge is pivotal for rational drug design, clinical efficacy optimization, and next-generation development strategies.
By analyzing patients’ tumor specimens, CaliHow identifies key signaling pathways, molecular interactions, and predictive biomarkers that inform patient stratification and responder profiling. These insights enable you to select the right patient populations, design adaptive trial strategies, and accelerate regulatory submissions with robust mechanistic evidence.
CaliHow bridges preclinical findings to clinical application, helping you de-risk development, optimize dosing strategies, and anticipate resistance mechanisms before they emerge in the clinic. With this clarity, you can enhance potency, engineer synergistic combinations, and build a precision medicine framework that maximizes therapeutic impact and durability.
Precision Target Assessment for Smarter Trials
CaliTarget goes far beyond measuring target expression, it quantifies how much and in which cellular subsets your target is expressed in intact patients’ tumor samples. This precision ensures your therapeutic is aligned with the right biology from the earliest stages of development.
But we don’t stop there. CaliTarget enables predictive indication selection, identifying tumor types most likely to respond based on target prevalence and microenvironment context. This insight supports basket-trial-like strategies before entering the clinic, guiding patient stratification, biomarker-driven enrollment, and adaptive trial design.
By integrating these translational insights, CaliTarget accelerates preclinical data to clinical decision-making, helping you de-risk clinical trials, prioritize high-value indications, and optimize resource allocation. The result: accelerated timelines, reduced attrition, and a clear path toward precision medicine and regulatory success.
Discover the Best Drug Combinations for Real Tumors
CaliPredict is your ultimate precision combination strategy platform. Powered by our proprietary algorithm, it interrogates hundreds of thousands of potential drug pairings to identify only the most clinically relevant and effective combinations for real-world tumors. This means you can amplify therapeutic impact and design smarter, more potent regimens from the start.
By integrating real tumor data with advanced computational modeling, CaliPredict uncovers synergistic mechanisms, predictive biomarkers, and resistance-prevention strategies that inform patient stratification and adaptive trial design. These insights enable you to select the right partners for your drug, prioritize high-value indications, and accelerate preclinical-to-clinical translation.
With CaliPredict, streamline development with reduced risk, reduce attrition, and build evidence packages that support regulatory submissions and companion diagnostic strategies—all while saving time and resources. The result: combination therapies engineered for maximum efficacy and durable patient benefit.
